Intestinal microflora and digestive toxicity of irinotecan in mice

Clinical Cancer Research

Volumn 12, Issue 4, 2006, Pages 1299-1307

  Brandi, Giovanni ^a,b   Dabard, Jean ^c   Raibaud, Pierre ^c   Di Battista, Monica ^a   Bridonneau, Chantal ^c   Pisi, Anna Maria ^a   Morselli Labate, Antonio Maria ^b   Pantaleo, Maria Abbondanza ^a   De Vivo, Antonello ^a   Biasco, Guido ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c CEMAGREF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; BETA GLUCURONIDASE; CARBOXYLESTERASE; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CANCER CHEMOTHERAPY; CECUM; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; GASTROINTESTINAL TOXICITY; GERMFREE ANIMAL; HISTOPATHOLOGY; ILEUM MUCOSA; INTESTINE EPITHELIUM; INTESTINE FLORA; JEJUNUM MUCOSA; LETHAL DOSE; MICROSCOPY; MOUSE; NONHUMAN; PANETH CELL; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CECUM; COLON; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; ILEUM; INTESTINAL MUCOSA; INTESTINES; JEJUNUM; MICE; MICE, INBRED C3H; MICROSCOPY, ELECTRON, SCANNING; NECROSIS; SPECIFIC PATHOGEN-FREE ORGANISMS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 33644775719     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0750     Document Type: Article

References (43)

1. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001;19:1501-18.
2. Saliba F, Hagipantelli R, Misset JL, et al. Pathophisiology and therapy of irinotecan induced delayed-onset diarrhoea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 1998;16: 2745-51.
3. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluoruracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-8.
4. Saltz LB, Cox JV, Blancke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Engl J Med 2000;343:905-14.
5. Wasserman E, Cuvier C, Lokiec F, et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol 1997; 17:1751-9.
6. Erlichmann C, Goldberg RM, O'Connell MJ. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2001;344:305.
7. Ikuno N, Soda H, Watanabe M, Oka M. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and caecum. J Natl Cancer Inst 1995; 87:1876-88.
8. Araki E, Ishikawa M, Iigico M, Koide T, Itabashi M, Hoshi A. Relationship between development of diarrhoea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and in the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 1993;84: 697-702.
9. Sears SC, Mac Nally PC, Bachinski SZ, Avery RM. Irinotecan (CPT-11) induced colitis: report of a case and review of Food and Drug Administration MEDWATCH reporting. Gastrointest Endosc 1997;50:841-4.
10. Takasuna K, Hagiwara T, Hirohashi M, et al. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996;56:3752-7.
11. Takasuna K, Hagiwara T, Hirohashi M, et al. Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 1998;42:280-6.
12. Kehrer DF, Sparreboom A, Verweij J, et al. Modulation of irinotecan-induced diarrhoea by cotreatment with neomycin in cancer patients. Clin Cancer Res 2001;7:1136-41.
13. Stupp R, Focan C, Sessa C, et al. Prophylactic use of antibiotics during treatment with CPT-11 (Campto) for metastatic colorectal cancer (MCC). A randomised multicentrictrial. Ann Oncol 1998;9:34.
14. Van Huyen JP, Bloch F, Attar A, et al. Diffuse mucosal damage in the large intestine associated with irinotecan (CPT-11). Dig Dis Sci 1998;43:2649-51.
15. Kruger WH, Bohlius J, Comely OA, et al. Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology. Ann Oncol 2005;16:1381-90.
16. Satoh Y. Effect of live and heat-killed bacteria on the secretory activity of Paneth cells in germ-free mice. Cell Tissue Res 1988;251:87-93.
17. Satoh Y. Atropine inhibits the degranulation of Paneth cells in ex-germ-free mice. Cell Tissue Res 1988;253:397-402.
18. Ouellette AJ, Bevins CL. Paneth cells defensins and innate immunity of the small bowel. Inflamm Bowel Dis 2001;7:43-50.
19. Drasar BS. The Bacterial flora of the intestine. In: Rowland IR, editor. Role of the gut flora in toxicity and cancer. San Diego: Academic Press, Inc.: 1988. p. 23-38.
20. Brandi G, Pisi AM, Biasco G. Ultrastructure et ecologie microbienne du tube digestif humain. EDRA. Milan: 1998. p. 68-142.
21. Mathijssen RH, Van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94.
22. Gadelle D, Raibaud P, Sacquet E. β-Glucuronidase activities of intestinal bacteria determined both in vitro and in vivo in gnotobiotic rats. Appl Environ Microbiol 1985;49:682-5.
23. Kobayashi K, Bouscarel B, Matsuzaki Y, Ceryak S, Kudoh S, Fromm H. pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells. Int J Cancer 1999;83:491-6.
24. Kaneda N, Nagata H, Furuta T, Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 1990;50: 1715-20.
25. Slatter JG, Schaaf LJ, Sams JP, et al. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C] CPT-11 in cancer patients. Drug Metab Dispos 2000;28:423-33.
26. Kehrer DF, Yamamoto W, Verweij J, de Jonge MJ, de Bruijn P Sparreboom A. Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. Clin Cancer Res 2000;6:3451-8.
27. Sparreboom A, De Jonge MJ, De Bruijn P, et al. irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin Cancer Res 1998;4:2747-54.
28. Savarese D, Al-Zoubi A, Boucher J. Glutamine for irinotecan diarrhoea. J Clin Oncol 2000;18:450-1.
29. Gonçalves E, Da Costa L, Abigerges D, Armand JP. A new enkephalinase inhibitor as an alternative to loperamide in the prevention of diarrhoea induced by CPT-11. J Clin Oncol 1995;13:289-95.
30. Zidan J, Haim N, Beny A, Stein M, Gez E, Kuten A. Octeotride in the treatment of severe chemotherapy-induced diarrhoea. Ann Oncol 2001;12:227-9.
31. Karthaus M, Ballo H, Aberhardt W, et al. Prospective, double-blind, placebo controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11) induced diarrhoea in patients with advanced colorectal cancer. Oncology 2005;68:326-32.
32. Govindarajan R, Heaton KM, Broadwater R, Zeitin A, Lang NP, Hauer-Jensen M. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet 2000;356:566-7.
33. Trifan OC, Durham WF, Salazarm VS, et al. Cyclooxygenase-2 inhibition with Celecoxib enhances antitumor efficacy and reduces diarrhoea side-effect of CPT-11. Cancer Res 2002;62:5778-84.
34. Shinoara H, Killion JJ, Kuniyasu H, Kumar R, Fidler IJ. Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002. Clin Cancer Res 1998; 4:2053-63.
35. Wadkins RM, Hyatt JL, Yoon KJP, et al. Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhoea: synthesis, quantitative structure-activity relationship analysis, and biological activity. Mol Pharmacol 2004;65:1336-43.
36. Ikegami T, Ha L, Arimori K, et al. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhoea. Cancer Res 2002;62: 179-87.
37. Takeda Y, Kobayashi K, Akyiama Y, et al. Prevention of irinotecan (CPT-11)-induced diarrhoea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer 2001;92:269-75.
38. Mori K, Kondo T, Kamaiyana T, Kano Y, Tominaga K. Preventive effect of Kampo medicine (Hangeshashinto) against irinotecan-induced diarrhoea in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2003;51:403-6.
39. Alimonti A, Satta F, Pavese I, Burattini E, Zoffoli V, Secchione A. Prevention of irinotecan plus 5-FU/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first line treatment of advanced colorectal cancer. Ann Oncol 2003;14:805-6.
40. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science 2001;292:115-8.
41. Zoetendal EG, Akkermans AD, De Vos WM. Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol 1998;64:3854-9.
42. Mathijssen RH, Verweij J, De Jonge MJ, Nooter K, Stoter G, Sparreboom A. Impact of body size measures on irinotecan clearance: alternative dose recommendations. J Clin Oncol 2002;20:81-7.
43. Vitek L, Zelenka J, Zadinova M, Malina J. The impact of intestinal microflora on serum bilirubin levels. J Hepatol 2005;42:238-43.